NVCR stock news · NovoCure Limited
Get alerts for NVCR
Follow NovoCure Limited (NVCR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NVCRThe average price target for NovoCure Limited has been cut from $25.71 to $21.33.
NeutralNovoCure's average analyst target fell from $25.71 to $21.33, but ratings remain split and the new target still suggests 62% potential upside. The story gives no clear change to its business outlook.
Evercore ISI Group says Novocure is still a good buy but has cut its price target from $23 to $20.
NeutralNovocure's analyst kept an Outperform rating but cut the share-price target. Those opposing signals do not show a clear change in the company's business outlook.
NovoCure says Japan's health officials approved its Optune Pax treatment for certain pancreatic cancer patients.
Good for NVCRNovoCure won Japanese approval for Optune Pax for a specific pancreatic cancer group. This opens a path to more use, though the filing gives no sales or patient-use figures.
NovoCure Ltd says a director is retiring, new directors are being chosen, and some officers are getting new pay deals.
NeutralNovoCure reported a director's retirement that the company says was routine. This governance update does not change our view of the company.